Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 954

2.

Gefitinib therapy for non-small cell lung cancer.

Birnbaum A, Ready N.

Curr Treat Options Oncol. 2005 Jan;6(1):75-81. Review.

PMID:
15610717
3.

New molecular targeted therapies integrated with radiation therapy in lung cancer.

Provencio M, Sánchez A, Garrido P, Valcárcel F.

Clin Lung Cancer. 2010 Mar 1;11(2):91-7. doi: 10.3816/CLC.2010.n.012. Review.

PMID:
20199974
4.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

5.

Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.

Herbst RS, Sandler AB.

Clin Lung Cancer. 2004 Dec;6 Suppl 1:S7-S19. Review.

PMID:
15638959
6.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.

PMID:
21684626
7.

Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.

Fuster LM, Sandler AB.

Clin Lung Cancer. 2004 Dec;6 Suppl 1:S24-9. Review.

PMID:
15638954
8.

EGFR pathway in advanced non-small cell lung cancer.

Merlo V, Longo M, Novello S, Scagliotti GV.

Front Biosci (Schol Ed). 2011 Jan 1;3:501-17. Review.

PMID:
21196393
9.

Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Wang J, Xia TY, Wang YJ, Li HQ, Li P, Wang JD, Chang DS, Liu LY, Di YP, Wang X, Wu WZ.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e59-65. doi: 10.1016/j.ijrobp.2010.12.035. Epub 2011 Feb 23.

PMID:
21345607
10.

Is there a role for cetuximab in non small cell lung cancer?

Morgensztern D, Govindan R.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4602-5. Review.

11.
12.

Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.

Langer CJ.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002. Review.

PMID:
14967461
13.

EGFR inhibition in NSCLC: the emerging role of cetuximab.

Herbst RS.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S41-51. Review.

PMID:
19780245
14.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
15.

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.

Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8. Review.

PMID:
21216486
16.

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F.

J Cell Physiol. 2005 Dec;205(3):355-63. Review.

PMID:
15895392
17.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

18.
19.

Epidermal growth factor receptor targeting in cancer.

Mendelsohn J, Baselga J.

Semin Oncol. 2006 Aug;33(4):369-85. Review.

PMID:
16890793
20.

The role of EGFR inhibitors in nonsmall cell lung cancer.

Ciardiello F, De Vita F, Orditura M, Tortora G.

Curr Opin Oncol. 2004 Mar;16(2):130-5. Review.

PMID:
15075904

Supplemental Content

Support Center